Stem Cell Clinic

I thought it was just a rash but rare cancer now covers 90% of my skin splitting my hands and feet open – The Sun

By Stem Cell Doctors

WHEN Tony Ferreira developed a small skin rash on his lower back - he assumed it would be gone in a few days.

And given the dad-of-one, 40, had always been fit and healthy, the last thing to cross his mind was that it could be cancer.

4

However, Tony's worst fears became a reality when the rash rapidly spread across his body - causing his feet and hands to split open.

Doctors soon diagnosed the gardener, from Jersey, with a rare form of non-Hodgkin lymphoma called Sezary syndrome - which has now affected about 90 per cent of his body.

Desperate to keep her husband alive, Tony's wife Osvalda is now pleading for a stem cell donor to come forward and save his life.

She said: "We pray that a stranger will help us to continue our lives together for many years to come."

We pray that a stranger will help us to continue our lives together for many years to come

Tony's nightmare first begun in 2012, when he noticed a small rash on his lower back which did not go away.

The rash quickly developed - causing his hands and feet would split open - and Tony then noticed lumps in his groin and under his arms.

Five years on, in 2017, medics diagnosed Tony, originally from Madeira, with a rare form of non-Hodgkin lymphoma called Sezary syndrome.

The condition causes white blood cells to become cancerous and aggressively attack the skin.

4

4

About 90 per cent of Tony's body is now affected by the rare cancer, and his best chance of survival is blood stem cell donation.

His wife is now desperately hoping a stem cell donor will come forward.

The charity DKMS is co-ordinating the worldwide search for a donor, but Tony's Portuguese heritage is making it much more difficult for him to find a match.

Tony's parents and four siblings have been checked as a potential match, but none are suitable.

In March, Tony's doctors decided to treat him with a new anti-cancer chemotherapy drug (mogamulizumab) but the trial was then delayed due to the Covid-19 pandemic.

Osvalda, who worked as a housekeeper for a care home in Jersey, had been keeping the family afloat financially, but was then advised to take temporary leave due to the risk she might contract Covid-19 and pass it on to her husband.

She said: "Tony's condition is bad enough, but for thousands of patients living with cancer in the UK, Covid-19 has delayed many treatments.

"We're not sure yet when we can begin travelling to London for treatment or what the new normal will look like.

"I long to hold Tony's hands again, without his protective gloves on.

4

What is Sezary syndrome?

Sezary syndrome is an aggressive form of cutaneous T-cell lymphoma which is a group of disorders that occur when T-cells (a type of white blood cell) become cancerous and affect the skin.

It is characterised by a widespread red rash that may cover most of the body, the presence of cancerous T cells (called Sezary cells) in the blood, and abnormally enlarged lymph nodes.

Although Sezary syndrome can affect people of all ages, it is most commonly diagnosed in adults over age 60.

The signs and symptoms of this condition can vary but may include:

Affected people may also have an increased risk of developing anotherlymphomaor other type ofcancer.

The exact cause of Sezary syndrome is currently unknown.

Source: Rare Diseases

Treatment varies based on the signs and symptoms present in each person and the severity of the condition.

"Tony has been wearing his blue plastic gloves so long now that I've almost forgotten how his hands feel without them.

"He has such strong hands and holding them would reassure me that everything is going to be all right."

Jonathan Pearce, chief executive officer at DKMS UK, said the charity had seen a 50 per cent drop in the number of people coming forward to be donors due to coronavirus.

He added: "We are hugely concerned about the impact Covid-19 is having on those who rely on a blood stem cell donor.

"While many stem cell transplants are still going ahead, the logistics around supporting blood stem cell donors to travel to hospital, and then arranging the transport of the stem cells to the transplant centre, have become much more challenging and complex.

Exclusive

BOUNCE BACK BRITONDad who beat virus after record 65 DAYS on ventilator leaves hospital

SPLASH OF COLOURWoman makes home unsellable after 30 years decorating and you'll see why

PURE EVILMother jailed after selling daughters to paedo before watching as he raped them

BIG FAT GYPSY FUNERALTraveller dad's tribute with floral KFC, Joop aftershave and SuBo pic

STUCK AT HOMESchools WON'T open for kids of key workers over summer holidays, No10 says

ZERO TOLERANCEBLM protesters in London hit with 5pm curfew as cops vow to stop violence

"There are also transplants that have been delayed, but once the pandemic is over we know there will be a backlog of patients in urgent need of an unrelated blood stem cell donor.

"Sadly though, in some of those cases there's a risk that the disease could progress further, and a transplant may no longer be possible once this is all over."

People can register for a swab kit here.

Read more:
I thought it was just a rash but rare cancer now covers 90% of my skin splitting my hands and feet open - The Sun

‘I was tired and sore and I thought I had a really bad cold’ – 9Honey

By Stem Cell Doctors

Amanda is one of the happiest people you'll ever meet. She's bright, bubbly and endlessly positive.

She's also living with blood cancer, and doctors told her it had most likely been in her system for a year before she was diagnosed in 2018.

The paediatric anesthesiologist and mother-of-two had been feeling tired, but she was living what she described as a "lovely hectic life". Her two daughters were 13 and 10 at time, so there was an easy explanation for her fatigue.

"I used to walk up the hill from Queensland Children's Hospital to the car park after work and I found myself out of breath," Amanda, 53, told 9Honey.

"I thought I was unfit, so I joined a gym."

By September that year she was feeling terrible, and during a family holiday for the school holidays she began "feeling really quite crap".

"I was tired and sore and I thought I had a really bad cold," she said.

She wasn't even able to do any of the driving back home, approximately five hours, and when they got home she went to bed.

That was a Saturday. By Sunday she was even worse, but thought it could be a repeat of a health scare she'd had a decade earlier.

"I'd had pneumonia 10 years ago and at first I didn't realise and kept on working. That was until I got so sick that I couldn't even get up for work one day," she said.

"My husband (Owen) rang the nanny and asked her to check up on me to see if I was alright. She told him, 'I can't wake her up.'"

In that instance, Owen came home and took Amanda to hospital for treatment, and she eventually recovered.

This time, she did have pneumonia again, but it wasn't from working too hard. She'd developed pneumonia because her immune system had been destroyed by a blood cancer called Multiple Myeloma.

Amanda's treating physician, Dr Ian Irving, a clinical haematologist, told 9Honey about the cancer and ways in which it is being treated. He works at the Icon Cancer Centre, Wesley and Mackay and is also the Group Medical Director of the Icon Group Board.

"It's an incurable blood cancer that develops from plasma cells, a type of white blood cell found in the bone marrow that form part of the immune system and help protect against infection," he said.

"Approximately 18,000 Australians are living with Multiple Myeloma at any given time, only half of whom will survive five years post- diagnosis."

Amanda knew her outcome was bleak after receiving her diagnosis.

"I thought, 'No I don't have it. That's something old people get, and then they die.' It really felt dismal," she said.

The mum was admitted to hospital for urgent treatment and was anaemic, although she says she still felt calm, she told 9Honey, because she and Owen, also a doctor, were used to clinical settings.

Amanda was even calm when later that night she started having trouble breathing. She mentioned it to the nurse. She didn't make a big deal about it at all.

"I told the nurse, 'I'm not breathing very well' and she checked my stats and said they weren't good," Amanda recalled.

"The ward doctor came down and did some tests. By that stage I was so tired and everyone was so lovely. When they said they were taking me to intensive care to ventilate me, I remember thinking it was a good idea because I was tired of breathing."

While she was being wheeled to ICU, hospital staff rang Owen and told him they were ventilating her because she was suffering from respiratory failure and they couldn't wait for him to arrive as her situation was critical.

"I hadn't really cottoned on that I may not wake up," she said.

"I think it was more alarming for Owen and the children because I was ventilated for two days."

Looking back, Amanda realises she was one of the lucky ones.

"I was young enough to get a stem cell transplant. If you are under 65-70 and you get Myeloma, you can get a stem cell transplant. They don't do it on older patients because they don't normally survive it."

Her treatment plan involved chemotherapy, steroids and stem cell transplants. Not all of it worked, but after two types of chemotherapy, the steroids which she says triggered ridiculous mood swings and two stem cell transplants in May and August 2019, the first of which took her six-and-a-half weeks to recover from.

Her hair fell out for the first time on Mother's Day.

Amanda hasn't yet returned to 'fully healthy', but is much better than she was when she was first diagnosed.

"There's evidence to show that exercise helps with the nausea of chemo and so I've been walking the dog and doing resistance sessions at the gym," she said.

"I used to swim in a pool but I can't now because of my low immune system. I can swim in the ocean but I'm photosensitive now and very intolerant to heat following treatment, so we go early in the morning or late in the afternoon."

The COVID-19 pandemic meant staying at home in isolation early in 2020, and remaining there. Amanda isn't sure when she'll be well enough to return to work as hospitals will expose her to too many illnesses.

"When we told the kids we tried not to make too much of big deal out of it," she said.

"I think they've done really well. Obviously it has been tough for them and we don't live near many relatives who can help us. They pitched in, cooking dinner and sorting and helping their dad out around the house."

"I think it was good for them. Now I am proud to say that I have two independent daughters who have learnt to do a lot for themselves. They will become strong, independent women."

Amanda has even enjoyed her long break from work as she's been able to spend more time at home with her children, now aged 15 and 12.

"During the 18 months I haven't worked I've been with the kids and they are teenagers so it has been nice to just be around them," she said.

"I'm not glad this happened but I have tried to morph this into something positive."

Amanda hopes that by sharing her story she raises public awareness of Multiple Myeloma.

"It is so important as it is a lot more common than people think," she said.

"It is important that more people understand the different ways that the disease presents so they can seek advice from their doctor should they experience any of the symptoms."

Amanda has been able to access a new combination of medications to keep her in remission, including some recently added to the PBS including REVLIMID (lenalidomide), bortezomib (Velcade) and dexamethasone (not new, has been around for years) (RVd).

Known as a triplet therapy, each drug in the RVd combination has a different mechanism of action to kill myeloma cells, and all work together to help fight the disease.

Amanda feels grateful to be able to access the new treatments which are working to keep her blood cancer at bay.

"It doesn't seem right that people get better access to treatment if they have more money, especially this year when many people have become unemployed due to COVID-19," she said.

Amanda had plenty of time to read during her time off from work and in between treatments. She said one book in particular helped her greatly: Curveballs by Emma Markezic who was diagnosed with aggressive breast cancer in her early thirties.

"In the book she talks about a happiness study where they followed someone who won a lot of money and someone who had suffered a spinal cord injury and would have to spend the rest of their lives in a wheelchair," Amanda recalled.

"At first, the money winner was happier and the spinal cord victim was unhappy but a year later they found their happiness score was the same. I've discovered that a lot of fighting cancer is getting your head around it and your attitude determines how you feel."

While returning to work isn't on the cards, Amanda has been training to be a Lifeline Crisis Worker.

"I got part of the way through the training when COVID hit, but I'm hoping to start again next month," she said.

Although she does hope to return to her original work as a paediatric anesthesiologist "once COVID is gone".

"You can't cure Multiple Myeloma, it's not like other cancers. I'm in remission and I take medication to keep me in remission, but you always have it.

"Sometimes it doesn't come back for 10 years, sometimes it comes back in three months. I just want to make the most out of my life and try and make a difference for someone else."

Find out more about Myeloma blood cancer by visiting the Myeloma Australia website.

Go here to see the original:
'I was tired and sore and I thought I had a really bad cold' - 9Honey

Study identifies mechanism affecting X chromosome that could lead to new disease therapies – Science Codex

By Embryonic Stem Cells

Researchers at Massachusetts General Hospital (MGH) have identified a key mechanism in X chromosome inactivation, a phenomenon that may hold clues that lead to treatments for certain rare congenital disorders.

Their findings, published in the journal Developmental Cell on June 11, 2020, may also aid in the creation of novel medicines for certain cancers.

Female humans and other mammals have two copies of the X chromosome in each of their cells. Both X chromosomes contain many genes, so only one of the pair can be active; having both X chromosomes expressing genes would be toxic to the cell.

For this reason, female mammals developed a mechanism called X chromosome inactivation, which silences one chromosome, explains Jeannie Lee, MD, PhD, of the Department of Molecular Biology at MGH, senior author of the Developmental Cell study.

Learning how to inactivate and reactivate an X chromosome would have important implications for medicine. A notable category of beneficiaries could be people with certain congenital diseases known as X-linked disorders, which are caused by mutations in genes on the X chromosome.

One example is Rett syndrome, a disorder brought on by a mutation in a gene called MECP2 that almost always occurs in girls and results in profound problems with language, learning, coordination, and other brain functions.

In theory, it may be possible to treat a disorder like Rett syndrome by reactivating the X chromosome. "Why don't we put the dormant X chromosome to work and rescue the cells that are lacking a proper copy of MECP2?" asks Lee.

The goal of X chromosome reactivation has led scientists to focus on epigenetic factors, which turn genes "on" or "off" without altering the genetic code. Silencing genes on the X chromosome occurs when a form of noncoding RNA called Xist spreads across the X chromosome, explains Lee.

However, Xist doesn't act alone: It must attract proteins called Polycomb repressive complexes (PRC) 1 and 2 to complete inactivation of the X chromosome.

But how Xist pulls in PRC1 and PRC2 had been unclear and the subject of debate. Research indicates that repeating sequences of nucleotides on Xist called Repeat A and Repeat B appear to act as magnets for these proteins. Yet some recent research suggests that Repeat A plays no role.

In the new study, Lee and her colleagues showed that both Repeat A and Repeat B are needed to attract PRC1 and PRC2 and complete X chromosome inactivation. By deleting Repeat A from Xist in mouse embryonic stem cells, they found that X chromosome inactivation is not only thwarted, but one X chromosome is eliminated entirely in order for the cells to survive in culture.

In human females, when one X chromosome is missing, the result is Turner syndrome, which affects stature, fertility, and other physical traits.

Understanding how Xist "recruits" PRC1 and PRC2 could have far-reaching implications, especially since the latter plays a key role in maintaining overall cell health.

"We think that through interfering with the Xist recruitment of Polycomb and other silencing complexes, we may eventually be able to treat X-linked diseases like Rett syndrome and perhaps even cancer," says Lee.

See the original post here:
Study identifies mechanism affecting X chromosome that could lead to new disease therapies - Science Codex

Cellular Reprogramming Tools Market to Witness Robust Expansion Throughout the F – News.MarketSizeForecasters.com

By Embryonic Stem Cells

Market Study Report, LLC, adds a comprehensive research of the ' Cellular Reprogramming Tools market' that mentions valuable insights pertaining to market share, profitability graph, market size, SWOT analysis, and regional proliferation of this industry. This study incorporates a disintegration of key drivers and challenges, industry participants, and application segments, devised by analyzing profuse information about this business space.

The research report on Cellular Reprogramming Tools market provides a granular assessment of this business vertical and includes information concerning the market tendencies such as revenue estimations, current remuneration, market valuation, and market size over the estimated timeframe.

Request a sample Report of Cellular Reprogramming Tools Market at:https://www.marketstudyreport.com/request-a-sample/2701683?utm_source=marketsizeforecasters.com&utm_medium=ADS

An overview of the performance assessment of the Cellular Reprogramming Tools market is enlisted. The document also comprises of crucial insights pertaining to the major industry trends and the expected growth rate of the said market. The study encompasses specifics related to the growth avenues as well as the restraining factors for this business space.

Major factors underlined in the Cellular Reprogramming Tools market report:

Considering the geographical landscape of the Cellular Reprogramming Tools market:

Cellular Reprogramming Tools Market Segmentation: North America, Europe, Asia-Pacific & Middle East and Africa.

A summary of the details offered in the Cellular Reprogramming Tools market report:

Ask for Discount on Cellular Reprogramming Tools Market Report at:https://www.marketstudyreport.com/check-for-discount/2701683?utm_source=marketsizeforecasters.com&utm_medium=ADS

An overview of the Cellular Reprogramming Tools market in terms of product type and application scope:

Product landscape:

Product types: Adult Stem Cells, Human Embryonic Stem Cells, Induced Pluripotent Stem Cells and Other

Key parameters included in the report:

Application Spectrum:

Application segmentation: Drug Development, Regenerative Medicine, Toxicity Test, Academic Research and Other

Specifics offered in report:

Additional information mentioned in the report:

Other insights regarding the competitive scenario of the Cellular Reprogramming Tools market:

Vendor base of Cellular Reprogramming Tools market: Celgene, FUJIFILM Holdings, BIOTIME, Advanced Cell Technology, Mesoblast, Human Longevity, Cynata, STEMCELL Technologies, Astellas Pharma, Osiris Therapeutics, EVOTEC and Japan Tissue Engineering

Key parameters as per the report:

Highlights of the report:

Key questions answered in the report:

For More Details On this Report: https://www.marketstudyreport.com/reports/global-cellular-reprogramming-tools-market-growth-status-and-outlook-2020-2025

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3: Cellular Reprogramming Tools Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

Chapter 4: Cellular Reprogramming Tools Market, By Region

Chapter 5: Company Profile

Business Overview

Financial Data

Product Landscape

Strategic Outlook

SWOT Analysis

Related Reports:

2. Global Deuterium-substituteddrugs Market Growth (Status and Outlook) 2020-2025Deuterium-substituteddrugs Market report covers the market landscape and its growth prospects over the coming years, the Report also brief deals with the product life cycle, comparing it to the relevant products from across industries that had already been commercialized details the potential for various applications, discussing about recent product innovations and gives an overview on potential regional market.Read More: https://www.marketstudyreport.com/reports/global-deuterium-substituteddrugs-market-growth-status-and-outlook-2020-2025

Read More Reports On: https://www.marketwatch.com/press-release/global-public-safety-drones-market-size-to-show-robust-growth-through-2027-2020-06-12?tesla=y

Read More Reports On: https://www.marketwatch.com/press-release/global-industrial-refrigeration-equipment-market-size-to-witness-prominent-gains-during-2020-2026-2020-06-06?tesla=y

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

See the original post here:
Cellular Reprogramming Tools Market to Witness Robust Expansion Throughout the F - News.MarketSizeForecasters.com

Exploring the Therapeutic Potential of ST266 Against Numerous Diseases Including COVID-19 – Technology Networks

By Embryonic Stem Cells

Noveome Biotherapeutics is a clinical-stage company focused on developing therapies for the regenerative repair of tissues. Their product ST266, a first-of-its-kind, multi-targeted, non-cellular platform biologic comprised of a complex mixture of biomolecules, is currently being evaluated as a potential treatment for the severe inflammatory response observed in the lungs of some COVID-19 patients.Technology Networks recently spoke with William J. Golden, Noveome Biotherapeutics Founder, Chairman and CEO, who explains the underlying basis for investigating ST266s potential against COVID-19. Golden also elaborates on many of the other indications for which ST266 is being developed to treat.Laura Lansdowne (LL): Could you provide our readers with a brief overview of Noveome Biotherapeutics?William J. Golden (WJG): Noveome is a clinical-stage biotherapeutics company located in Pittsburgh, PA. The company was founded in 2000 by Bill Golden and Lancet Capital. The group was interested in exploring non-embryonic stem cells and identified a technology at the University of Pittsburgh that was using cells derived from human amnion, a membrane that closely covers the fetus during development. The company, named Kytaron Technologies, Inc. at the time, licensed that amnion cell technology but, ultimately, Noveome scientists were able to discover, develop and patent their own unique population of cells, called Amnion-derived Multipotential Progenitor (AMP) cells, using a proprietary culture method that follows current Good Manufacturing Practice (cGMP) regulations. These novel cells were used to produce our product, ST266.LL: What is ST266? Could you elaborate on its mechanism of action in relation to the healing process?WJG: Noveomes product, ST266, is the secretome produced by the AMP cells. It is a completely cell-free solution and is comprised of hundreds of biologically active molecules, including cytokines and growth factors. Interestingly, these cytokines and growth factors exist at very low physiological levels ranging from pg/mL ng/mL concentrations.1 The fact that such low concentrations of these molecules are biologically active is quite remarkable when you consider that traditional protein-based therapies are usually administered at concentrations that are orders of magnitude greater than the concentrations found in ST266.Because the composition of ST266 is so complex, its multiple mechanisms of action have only been partially elucidated. Clinical and preclinical studies have shown ST266 to be anti-inflammatory,2,3 promote wound healing,4,5 reduce apoptosis, reduce vascular permeability (manuscript in preparation), and restore cellular homeostasis.3 Preclinical studies have also shown ST266 to be neuroprotective. In a traumatic brain injury model, ST266 significantly protected against reactive gliosis, suggesting potent anti-inflammatory activity, and resulted in significant recovery of rotarod motor function.6,7 In another study, ST266 was tested in the experimental autoimmune encephalopathy (EAE) mouse model of multiple sclerosis (MS). In this model, the mice develop optic neuritis, which is among the presenting symptoms of MS in humans. ST266 was administered to the nares of mice 15 or 22 days after disease induction. ST266 is absorbed via capillary action along the olfactory nerves which bypasses the blood-brain barrier. This unique route of administration allows for the delivery of high molecular weight biologics to the optic nerve of the eye and the central nervous system. ST266 attenuated visual dysfunction, prevented retinal ganglion cell (RGC) loss, reduced inflammation, and decreased the rate of demyelination of the optic nerve in EAE mice.3Mechanistically, ST266 simultaneously acts on multiple cell receptor-activated and intracellular signaling pathways. For example, in the EAE MS model, neuroprotective effects involved oxidative stress reduction, SIRT1-mediated mitochondrial function promotion, and pAKT signaling.3 In a Phase 2 UV light burn study, ST266 reduced erythema and DNA damage and increased the expression of XPA DNA repair proteins.2Importantly, ST266 has a proven clinical safety profile. It has been administered to 243 patients by various routes of administration (topical skin, topical ocular, topical oral, targeted intranasal), and no drug-related serious adverse events have been reported. Preclinical studies of systemically administered ST266 have also yielded no drug-related safety concerns.LL: For what indications is ST266 currently being evaluated as a treatment?WJG: We refer to ST266 as a platform biologic. By this, we mean that ST266 is one product that has the potential to treat numerous and varied diseases. In the clinic, we have shown anti-inflammatory activity when ST266 is applied topically to UV light-burned the skin2 and topical application to the gums of patients with gingivitis and periodontitis showed a reduction in proinflammatory cytokines in the patients crevicular fluid (manuscript in preparation). We are currently conducting a Phase 2 open label trial of ST266 to treat persistent corneal epithelial defects (PEDs) when applied topically to the eye. Results from this trial will be published soon. We are currently planning a Phase 2b multi-center, randomized, double-masked trial to further evaluate the safety and efficacy of ST266 in this indication. Finally, we are conducting a Phase 1 study in patients at risk for developing glaucoma. This study is using the intranasal route of delivery described above in combination with a novel delivery device. The goal is to deliver ST266 directly to the optic nerve, where it can protect the RGCs that are damaged in glaucoma. We envision this route of delivery will be applicable to central nervous system and other back-of-the eye indications.We also have several ongoing preclinical programs that are evaluating systemically administered ST266 for more generalized inflammatory conditions. These data are not yet published but combined with the data we have compiled in preclinical and clinical studies of topical skin, topical oral and topical ocular administration, we believe ST266 has the potential to be an effective therapy for numerous systemic inflammatory conditions.LL: Could you elaborate on the underlying basis for your evaluation of ST266 as a potential treatment for COVID-19?WJG: As you know, a major complication of COVID-19 is the severe inflammatory response seen in the lungs of some patients. This response is called cytokine storm or cytokine release syndrome. As the pandemic continues and more data have become available, it is now known that the cytokine storm does not just affect the lungs. Multi-organ damage occurs in many of these patients. We believe that systemic delivery of ST266 and its anti-inflammatory activity has the potential to calm the storm. Our as-yet-unpublished preclinical studies with intravenous ST266 support this hypothesis and we are moving rapidly to initiate intravenous ST266 in a Phase 1 study. Once safety in humans is established by this route of administration, we will commence Phase 2 studies in COVID-19 patients.William J. Golden was speaking to Laura Elizabeth Lansdowne, Senior Science Writer for Technology Networks.References

1. Steed, DL, C Trumpower, D Duffy, C Smith, V Marshall, R Rupp, and M Robson. (2008). Amnion-Derived Cellular Cytokine Solution: A Physiological Combination of Cytokines for Wound Healing. Eplasty 8: 15765.

2. Guan, Linna, Amanda Suggs, Emily Galan, Minh Lam, and Elma D. Baron. (2017). Topical Application of ST266 Reduces UV-Induced Skin Damage. Clinical, Cosmetic and Investigational Dermatology. DOI: https://doi.org/10.2147/CCID.S147112.

3. Khan, Reas S, Kimberly Dine, Bailey Bauman, Michael Lorentsen, Lisa Lin, Helayna Brown, Leah R Hanson, et al. (2017). Intranasal Delivery of A Novel Amnion Cell Secretome Prevents Neuronal Damage and Preserves Function In A Mouse Multiple Sclerosis Model. Scientific Reports. DOI: https://doi.org/10.1038/srep41768.

4. Bergmann, Juri, Florian Hackl, Taro Koyama, Pejman Aflaki, Charlotte a Smith, Martin C Robson, and Elof Eriksson. (2009). The Effect of Amnion-Derived Cellular Cytokine Solution on the Epithelialization of Partial-Thickness Donor Site Wounds in Normal and Streptozotocin-Induced Diabetic Swine. Eplasty 9: e49.

5. Franz, Michael G, Wyatt G Payne, Liyu Xing, D K Naidu, R E Salas, Vivienne S Marshall, C J Trumpower, Charlotte A Smith, David L Steed, and M C Robson. (2008). The Use of Amnion-Derived Cellular Cytokine Solution to Improve Healing in Acute and Chronic Wound Models. Eplasty 8: e21.

6. Deng-Bryant, Ying, Zhiyong Chen, Christopher van der Merwe, Zhilin Liao, Jitendra R Dave, Randall Rupp, Deborah a Shear, and Frank C Tortella. (2012). Long-Term Administration of Amnion-Derived Cellular Cytokine Suspension Promotes Functional Recovery in a Model of Penetrating Ballistic-like Brain Injury. The Journal of Trauma and Acute Care Surgery DOI: https://doi.org/10.1097/TA.0b013e3182625f5f.

7. Deng-Bryant, Ying, Ryan D. Readnower, Lai Yee Leung, Tracy L. Cunningham, Deborah A. Shear, and Frank C. Tortella. (2015). Treatment with Amnion-Derived Cellular Cytokine Solution (ACCS) Induces Persistent Motor Improvement and Ameliorates Neuroinflammation in a Rat Model of Penetrating Ballistic-like Brain Injury. Restorative Neurology and Neuroscience. DOI: https://doi.org/10.3233/RNN-140455.

Original post:
Exploring the Therapeutic Potential of ST266 Against Numerous Diseases Including COVID-19 - Technology Networks

Assisted fertilization, the referendum 15 years ago – NJ MMA News

By Embryonic Stem Cells

Years 15 have passed since the popular referendum on the repeal of many of the prohibitions imposed by the law 40/04. The quorum was not reached, but the 12 and the 13 June 2005, the 80% of those who went to vote asked that the prohibitions on assisted reproduction and research on embryonic stem cells embryonic were canceled. Over the years it was the courts that lifted the bans (three out of four), thanks to the appeals promoted with the couples and coordinated by the lawyer Filomena Gallo, secretary of the Luca Coscioni association, which protects the right to health and science, and with many patient associations.

Since then the heterologous fertilization , the are possible fertilization of more than three gametes by canceling the obligation of simultaneous implantation, and access to medically assisted procreation for couples fertile carriers of genetic pathologies . Only the ban on scientific research on embryos unsuitable for pregnancy remains. But, in conjunction with this important anniversary, the Coscioni association also announces further legal actions to guarantee preimplantation diagnoses in the Lea (the essential levels of assistance, i.e. the services and services that the National Health Service is required to provide to all citizens), the free research on embryos, the cancellation of the age limit and the regulation of gestational support for others.

The dream of being able to hold your child in your arms for hundreds of aspiring mothers and fathers was broken with a referendum boycotted by political and Vatican interference, explains Filomena Gallo -. Thanks to the determination of some couples, that joy was achieved later, with the decisions of the courts aroused by actions that, according to the latest available data, those of the 2017, have led to the birth of at least 705 children thanks to the preimplantation diagnosis, for a total of 14 . 000 born per year with all medically assisted procreation techniques in force in Italy today .

And, now, we are active at all levels to eliminate the last ban on the referendum , that of scientific research on embryos not suitable for pregnancy and in general to achieve the goal of full protection of the right to health. We recently reiterated to the Government the urgent need to include the preimplantation genetic diagnosis among the Lea , a necessary action to avoid abortions .

In addition, the association is asking the regions to extend the age limit currently provided. For now only Campania, Lazio and Tuscany have reacted positively. We also asked gamete donors for a refund.

Coronavirus, stop assisted fertilization. 4500 children less

Valencia, inside the laboratory where children are born

My husband and I, parents thanks to assisted fertilization

In vitro fertilization, I was not wrong

Read this article:
Assisted fertilization, the referendum 15 years ago - NJ MMA News

Growth in Sales of Cell Banking Outsourcing Market to Push Revenue Growth in the Market – The Canton Independent Sentinel

By Embryonic Stem Cells

A cell bank refers to a facility that store cells derived from various body fluids and organ tissue for future needs. The bank store the cells with detailed characterization of the cell line hence decrease the chances of cross contamination. Cell banking outsourcing industry involves collection, storage, characterization, and testing of cells, cell lines, and tissues. Cell banks provide cells, cell lines, and tissues for R&D, production of biopharmaceuticals with maximum effectiveness and minimal adverse events. The process for storage of cells includes first proliferation of cells that multiplied in large number of identical cells and then stored into cryovials for future use. Cells mainly used in the regenerative medicine production. Increasing demand of stem cell therapies and number of cell banks expected to boost the global market.

Get Free Sample Copy With Impact Analysis Of COVID-19 Of Market Report @https://www.persistencemarketresearch.com/samples/8026

Global cell banking outsourcing market segmented based on bank type, cell type, phase, and geography. Based on bank type market is further segmented into master cell banking, working cell banking, and viral cell banking. Cell type segment further divided based on stem cell banking and non-stem cell banking. Stem cell banking includes dental, adult, cord, embryonic, and IPS stem cell banking. Based on phase, the global cell banking outsourcing market segmented into preparation, storage, testing, and characterization. Geographically, market divided into North America, Europe, Asia Pacific, Latin America, and Middle East Africa. By considering bank type master cell banking accounted largest share owing to longer duration of preservation that would attract the researcher. Stem cell banking accounted larger share than non-stem cell banking due to lower risk of contamination.

In stem cell banking cord stem cell banking accounted larger share by revenue in 2014 due to increasing number of cord blood banks, and services globally. Additionally, donor convenience, immediate availability, lower risk of viral contamination is major driving factors for cord stem cell banking. In bank phase, segment storage phase accounted largest share and expected to maintain its share due to development of sophisticated preservation technologies such as cryopreservation technique. Geographically, North America accounted largest share due to high number of ongoing research projects. However, Asia Pacific expected to show significant growth during forecast period owing to supportive government initiatives coupled with increasing awareness about cell therapies.

The global cell banking outsourcing market is witnessing lucrative growth during forecast period due to increased research in cell line development owing to rise in incidence of infectious chronic disorder, and cancer. Additionally, development of advanced preservation techniques, increasing adoption to the stem cell therapies, rise in cell bank facilities across globe, and moving focus of researcher towards stem cell therapies would drive the market. However, high cost of therapies, availability of right donors, and legal and changing ethical issues during collection across the globe are major restraint of the market. Risk associated with cell line banking is contamination of cell lines by manual errors or environmental conditions hence care should be taken during storing and handling of cells.

You Can Buy This PMR Healthcare Report From Here @ https://www.persistencemarketresearch.com/checkout/8026

Major player in cell banking outsourcing market include BioOutsource (Sartorious), BioReliance, BSL Bioservice, Charles River Laboratories, Cleancells, CordLife, Covance, Cryobanks International India, Cryo-Cell International Inc., GlobalStem Inc., Goodwin Biotechnology Inc., LifeCell International Pvt. Ltd., and Lonza. Additionally, PXTherapeutics SA, Reliance Life Sciences, SGS Life Sciences, Texcell, Toxikon Corporation, Tran-Scell Biologics, Pvt. Ltd., and Wuxi Apptec are other companies in global cell banking outsourcing market.

Rustil is a regular contributor to blog , Specializing in Industry Research and Forecast

Visit link:
Growth in Sales of Cell Banking Outsourcing Market to Push Revenue Growth in the Market - The Canton Independent Sentinel

Explore the Mice Model Market: CRISPR As a Powerful Tool in the Field of BioMedical Research – WhaTech Technology and Markets News

By Embryonic Stem Cells

[269 Pages Report] Mice Model Market report categorizes the Global market by Type (Inbred, Knockout, Hybrid), Technology (CRISPR, Microinjection), Application (Oncology, Diabetes), Service (Breeding, Quarantine, Genetic testing) & Care Products (Bedding, Feed) & Geography. COVID-19 impact on Mice Model Industry.

MarketsandMarkets forecaststhemice model marketto grow from USD 1.11 billion in 2016 to USD 1.59 billion by 2021, at a Compound Annual Growth Rate (CAGR) of 7.5%during the forecast period. The growth of the market can be attributed to ongoing innovations in mice models, continuous support in the form of investments and grants, and growing demand for humanized mice models.

By Technology, the CRISPR technology segment to account for the largest share of the global mice model market in 2016

Based on technology, the market is segmented into CRISPR/Cas9, microinjection, embryonic stem cell injection, nuclear transfer, and other technologies. The CRISPR technology accounts for the largest share of the global mice model market in 2016.

The large share of this segment can primarily be attributed to the fact that CRISPR is the most widely used technique due to the various advantages associated with it, such as ease of design, high efficiency, and relatively low cost.

Emergence of CRISPR as a powerful tool in the field of biomedical research

CRISPR (clustered, regularly interspaced, short palindromic repeat) is seen as a revolutionary technology for gene editing. The use of Cas9 enzyme differentiates CRISPR from other forms of genetic modification.

This technology edits and rearranges genes by cutting out damaged or unwanted parts of the DNA, allowing the remaining DNA to be rearranged in a new way.

Moreover, this fast, precise, and easy-to-use technology is considered as a revolutionary tool in research, and there is an intense interest to validate its therapeutic usage in humans.

CRISPR was first shown to work in mouse and human cells less than three years ago and has already been applied to a range of biological systems and disease areas. CRISPR is used in the development of genetically modified mice strains, making the process not only quicker but also less expensive.

Thus, the emergence of CRISPR as a popular technology is expected to offer potential growth opportunities in the coming years.

Download PDF Brochure @www.marketsandmarkets.com/pdfdownsp?id=1308

North America to account for the largest market size during the forecast period.

North America is accounted for the largest share of the market. North Americas leadership in the market can be attributed to the increased focus on biomedical research in the U.S., rising demands for monoclonal antibody production, nexus between CROs and pharmaceutical companies, continued and responsible use of animals ensured by animal care organizations, rising preclinical activities by CROs and pharmaceutical companies, and growing stem cell research in Canada.

Asia Pacific is the third-largest market for mice model market and is slated to register the highest CAGR of 7.9% during the forecast period. The high growth in the region can be attributed to less stringent regulations on the use of animal models for research in the region, international alliances for R&D activities in China, growth in regenerative medicine, biomedical, and medical research in Japan, growing presence of global players, development of bioclusters to boost the biotechnology industry in India, ongoing biomedical research activities in Australia, and rising pharmaceutical & biotechnology R&D activities.

Key Market Players

Charles River Laboratories International, Inc. (U.S.), The Jackson Laboratory (U.S.), Taconic Biosciences, Inc.(U.S.), TRANS GENIC Inc. (Japan), Horizon Discovery Group plc (U.S.), Envigo (U.K.), Laboratory Corporation of America Holdings (U.S.), and genOway (France).

Charles River Laboratories is a leading player in the global mice models and services market. The mice models offered by the company include inbred, outbred, hybrid, immunodeficient, congenic, and genetically engineered mice.

The company also offers mice modeling services such as surgical services for rodents, genetic testing services, colony management services, and health monitoring services. The strong portfolio enables the company to increase collaboration with clientsfrom early lead generation to candidate selection.

Request for Sample Pages @www.marketsandmarkets.com/requestsp?id=1308

Recent Developments

Critical questions the report answers:

Inquiry About Mice Model Market @www.marketsandmarkets.com/Enquirysp?id=1308

This email address is being protected from spambots. You need JavaScript enabled to view it.

Visit link:
Explore the Mice Model Market: CRISPR As a Powerful Tool in the Field of BioMedical Research - WhaTech Technology and Markets News

Regenerative Therapy Options for Horses With Osteoarthritis – TheHorse.com

By Stem Cell Treatment

Biologic, or regenerative, therapies have altered the way many equine veterinarians treat problematic joints. Some of the most mainstream and popular modalities they currently use to manage osteoarthritis (OA) in horses are autologous conditioned serum, autologous protein solution, platelet-rich plasma, and mesenchymal stem cells.

Most biologic therapies involve collecting and concentrating the horses natural anti-inflammatory and regenerative proteins or cells so they can be injected into an area of pathology (disease or damage) in the same horse.

Autologous conditioned serum is a cell-free extract of whole blood that has been processed to contain high concentrations of interleukin-1 receptor antagonist protein (IRAP), a naturally occurring anti-inflammatory protein within the body. It is marketed under the trade names IRAP and IRAP II.

When preparing ACS, veterinarians collect venous blood in a proprietary syringe system that encourages porous glass beads to bind with white blood cells. During an incubation process the bound white cells release high concentrations of IRAP. The veterinarian then draws the serum off into small portions and freezes it for future injection into arthritic joints. In clinical studies of ACS, researchers have reported improved synovial membrane (joint surface lining) health, stimulation of natural IRAP production, and improved lameness.

Platelet rich plasma is blood plasma thats been centrifuged or filtrated to have a higher concentration of platelets than whole blood. Many horse owners are familiar with PRP and its use in tendon and ligament injuries; however, veterinarians are using it more regularly for treating joint disease.

One of platelets roles in the body is to modulate tissue healing. They do so by releasing growth factors and signaling molecules that initiate repair and promote anabolic (supporting tissue growth) effects. Veterinarians have capitalized on this ability by injecting high concentrations of platelets directly into damaged or inflamed regions. Because many PRP systems allow for stallside preparation, it is a convenient option for immediate treatment without the hassle of incubation or culturing in the lab, as is the case with ACS and stem cell preparation, respectively.

Historically, equine veterinarians have primarily used PRP to help treat soft tissue injuries. More recent work has led to intra-articular (in the joint) use with promising results. Although researchers have demonstrated how platelet-derived products work in vitro (in the lab) and veterinarians have seen promising anecdotal results in vivo (in the live horse), theyve yet to produce evidence-based confirmation of its clinical efficacy.

Mark Revenaugh, DVM, owner of Northwest Equine Performance, in Mulino, Oregon, says the main factors standing between researchers ability to gather objective data and establish a consensus on PRPs efficacy are the high variability among preparation systems, individual patient reactivity to the product, and an unknown ideal concentration of platelets for particular injuries.

Most practitioners cant always check how many platelets are being used, he says. Depending on the system, one veterinarian may be using 100,000 platelets/milliliter and another veterinarian may be using 1 billion platelets/milliliter. These are not the same treatments, even though both are called PRP. I would love to see an industry standard develop.

Overall, PRPs positive anecdotal results and relatively easy preparation make it a useful option for treating osteoarthritis (OA) in horses.

Autologous protein solution (marketed under the trade name Pro-Stride) is essentially a hybrid of ACS and PRP. Its two-step stallside preparation process involves separating whole blood and sequestering white blood cells and platelets in a small fraction of plasma. The veterinarian then concentrates the separate blood components by filtration, leaving a solution of white blood cells, platelets, and serum proteins that provides the anti-inflammatory mediators of IRAP and the platelet-derived growth factors of PRP.

In a 2014 study out of The Ohio State University, researchers revealed that an intra-articular APS injection can significantly improve lameness, weight-bearing symmetry, and range of joint motion in horses that dont have severe lameness or significant compromise to the joint structure.

Mesenchymal stems cells are adult stem cells that can direct regeneration and repair of damaged tissue. Veterinarians have used this type of stem cell as a treatment strategy for equine soft tissue injury for some time; its only recently that veterinarians have begun using them to treat OA, and its not fully clear how they work in this capacity. Researchers working on early stem cell studies hoped to establish evidence that stem cells injected into regions of injury would develop into the respective tissue. While this hypothesis proved to be incorrect, continued research has revealed that these cells might instead have anti-inflammatory effects and the ability to recruit other stem cells to the area that could, in fact, heal damaged tissue.

The two most common forms of mesenchymal stem cells are adipose (fat)-derived and bone-marrow-derived. Some study results have shown that bone marrow sources yield smaller concentrations thanbut are superior toadipose sources in their ability to differentiate into musculoskeletal tissue. Some encouraging data supporting the use of mesenchymal stem cells for treating OA exists, but researchers have only published a small number of studies with promising results. Equine veterinarians have used MSCs to treat intra-articular soft tissue injury (meniscal and cruciate damagecartilaginous tissues and ligaments that support the stifle), with successful anecdotal results. Theyve reported more variable outcomes when using it for primary intra-articular injuries.

Carter Judy, DVM, Dipl. ACVS, staff surgeon at Alamo Pintado Equine Medical Center, in Los Olivos, California, says he currently prefers to use PRP and APS for OA treatment over MSCs. However, he admits there is much to be discovered. What will be interesting to see is how manipulating the cells and providing them with different signals and markers can make their efficacy much more potent and focused, he says.

When weighing treatment options for horses with OA, veterinarians should base their decision to use a certain biologic modality on its cost, availability, and how a horse has responded previously.

Our knowledge base of how the biologics work is improving, but we are in the infancy of understanding, Judy says. Much of the use is based on the clinical response as much as is it on the scientific data.

Read the original here:
Regenerative Therapy Options for Horses With Osteoarthritis - TheHorse.com

Dasatinib-Containing Induction Therapy Associated With High Rates of Allogeneic HSCT in Newly Diagnosed Ph+ ALL – Cancer Therapy Advisor

By Stem Cell Treatment

Results from a phase 2 study showed that a 2-step induction regimen involving dasatinib and intensive chemotherapy was associated with high rates of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients younger than 65 years with Philadelphia chromosome-positive (Ph+), newly diagnosed acute lymphoblastic leukemia (ALL), as well as improved 3-year overall survival (OS) rates for those undergoing allo-HSCT compared with those who did not. These findings were presented during the Virtual Edition of the 25th European Hematology Association (EHA) Annual Congress.1

While the standard-of-care in Japan for the treatment of younger patients with newly diagnosed Ph+ ALL is allo-HSCT preceded by imatinib plus intensive chemotherapy induction therapy, 30% to 40% of patients treated with this regimen in clinical trials were unable to undergo allo-HSCT due to older age, early relapse, or therapy-related death.2 Hence, less toxic and more effective pretransplant regimens are needed for this population of patients.

In an open-label, single-arm, multicenter, phase 2 Japan Adult Leukemia Study Group (JALSG) Ph+ALL213 study (UMIN000012173), patients with newly diagnosed Ph+ALL aged 15 to 64 years received 7 days of prephase therapy with prednisone, followed by the following steps: (1) induction therapy involving treatment with dasatinib plus prednisone; (2) intensive consolidation therapy including dasatinib, cyclophosphamide, daunorubicin, vincristine and prednisone, followed by 4 alternating cycles of 2 different consolidation therapy regimens. Maintenance therapy involved treatment with dasatinib, vincristine, and prednisone; however, patients who achieved hematologic complete remission (HCR) following consolidation therapy who had an appropriate donor underwent allo-HSCT during consolidation. The primary study endpoint was 3-year event-free survival (EFS) following induction. Secondary study endpoints included HCR, safety, and the efficacy of allo-HSCT (ie, relapse-free survival, relapse rate, and non-relapse mortality).1,3

Previously reported results demonstrated that both 3-year EFS and 3-year OS were improved for the overall study population of patients with newly diagnosed Ph+ ALL receiving dasatinib-based therapy compared with imatinib-based induction therapy.3

The analysis reported here included 78 of the 81 patients enrolled in this study, patients had a median age of 45 years and 32.1% of patients were 55 years or older. The rate of HCR after induction therapy was 100%, and 21.8%, 52.6% and 57.7% achieved molecular complete remission (MCR) after induction therapy, intensive consolidation therapy, and the first cycle of consolidation therapy, respectively. Of the 58 patients who underwent allo-HSCT, 75.9% had achieved MCR prior to allo-HSCT. No induction therapy-related deaths were reported.

Of the 58 (74.4%) patients who underwent allo-HSCT, the rates of relapse, relapse mortality, and transplant-related relapse mortality were 15.5%, 8.6%, and 10.3%, respectively. A cross-study comparison of these results with the PH+ALL202 study involving imatinib-based induction therapy did not show significant differences in these rates.1,2

At a median follow-up of 4 years, the rates of 3-year EFS and 3-year OS for the overall study group and the subgroup of those undergoing allo-HSCT were 66.2% and 80.5% compared with 74.1% and 84.1%, respectively.

In their concluding remarks, the study authors noted that this study demonstrated [dasatinib]-combined 2-step induction improved pretransplant treatment, which facilitated [allo-HSCT] and resulted in significantly improved survival.

Read more of Cancer Therapy Advisors coverage of the EHA virtual meeting by visiting the conference page.

References

Continue reading here:
Dasatinib-Containing Induction Therapy Associated With High Rates of Allogeneic HSCT in Newly Diagnosed Ph+ ALL - Cancer Therapy Advisor

→←